Signal transduction

Signal transduction
cybertory · CC BY-SA 3.0 · source
Name	Signal transduction
Classification	Biological process
Organism	Human, Escherichia coli
Discovered	Sydney Brenner, Francis Crick

Signal transduction

Signal transduction is the process by which cells convert external or internal cues into biochemical responses that alter cellular state. It underlies processes studied by Craig Venter, James Watson, Rosalind Franklin, Barbara McClintock, Emil Theodor Kocher, and informs work at institutions such as the Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, Max Planck Society, and National Institutes of Health. Research into signaling intersects historical projects like the Human Genome Project, applied efforts at Genentech, and translational programs at Mayo Clinic and Johns Hopkins Hospital.

Overview

Cellular signaling links receptors on membranes to intracellular effectors through cascades studied in model systems including Drosophila melanogaster, Caenorhabditis elegans, Mus musculus, Saccharomyces cerevisiae, and Arabidopsis thaliana. Key conceptual advances trace to experiments by Sydney Brenner, Francis Crick, and laboratories at Cambridge University and Stanford University, which mapped components of pathways such as those involving G protein-coupled receptor homologs, receptor tyrosine kinases characterized by teams at Harvard University and MIT, and second messenger systems explored in work by Nobel Prize in Physiology or Medicine recipients. The field integrates structural biology from European Molecular Biology Laboratory and cryo-EM facilities at Max Planck Institute.

Molecular components and mechanisms

Receptors include families with archetypes researched by Kobilka Lab and Schiøtz Group: G protein-coupled receptors, receptor tyrosine kinases exemplified by EGFR, and toll-like receptors studied in labs at Rockefeller University. Intracellular transducers encompass heterotrimeric G proteins characterized by Alfred G. Gilman and monomeric GTPases like Ras analyzed in studies by C. V. Raman Institute-affiliated groups. Second messengers such as cyclic AMP, calcium ions, and inositol trisphosphate were elucidated in experiments linked to Sutherland Lab and the Nobel Prize–winning work of Earl Sutherland. Effector enzymes include kinases (e.g., the MAPK family), phosphatases investigated at Pasteur Institute, ubiquitin ligases whose pathways were mapped by researchers at Max Planck Institute of Biochemistry, and transcription factors like NF-κB whose regulation was probed at University of California, San Francisco. Membrane microdomains and scaffolding proteins were characterized through collaborations involving European Synchrotron Radiation Facility and EMBL.

Major signaling pathways

Canonical pathways include the Ras-MAPK cascade studied in cancer centers such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute; the PI3K-Akt axis investigated in work at University of Cambridge; the Wnt pathway explored in labs at Whitehead Institute; the Notch pathway discovered by groups at UC Berkeley and Columbia University; the TGF-β signaling network described in studies associated with Yale University; and immune signaling routes like JAK-STAT examined at Imperial College London. Developmental signaling paradigms from Hedgehog signaling were defined through research at Stanford University and University of Edinburgh. Cross-talk among pathways was mapped in consortium projects such as those involving the European Molecular Biology Laboratory and the Wellcome Trust.

Cellular responses and outcomes

Signaling controls outcomes including proliferation, differentiation, apoptosis, migration, and metabolism—phenotypes studied in contexts ranging from HeLa cell research at Johns Hopkins University to stem cell work at Karolinska Institute and Salk Institute. In development, pathways characterized in Drosophila melanogaster and Xenopus laevis regulate pattern formation described by investigators at Princeton University and Harvard University. Immune activation traced through signaling modules is central to vaccines developed by teams at Pasteur Institute and CDC. Metabolic regulation linked to signaling cascades informs research at Cold Spring Harbor Laboratory and translational medicine at Cleveland Clinic.

Regulation and feedback

Negative and positive feedback loops were delineated in theoretical and experimental work involving Alan Turing-derived patterning concepts and systems biology groups at Santa Fe Institute and Institute for Systems Biology. Post-translational modifications such as phosphorylation, ubiquitination, methylation, and acetylation are mediated by enzymes discovered at institutions like NIH and Max Planck Institute, producing regulatory networks described in computational models from MIT and ETH Zurich. Crosstalk with metabolic sensors including AMPK and nutrient-sensing complexes investigated at University of Oxford imposes context dependence and robustness, while scaffold proteins and endocytic trafficking mapped at Yale University modulate signaling dynamics.

Methods and experimental approaches

Experimental tools include genetic screens pioneered by Nobel Prize in Physiology or Medicine winners such as Sydney Brenner, biochemical assays developed at Rockefeller University, live-cell imaging enabled by microscopes from ZEISS and cryo-EM advances at EMBL, mass spectrometry platforms at National Institute of Standards and Technology, and single-cell RNA-sequencing methods advanced by groups at Broad Institute and Wellcome Sanger Institute. Structural insights derive from X-ray crystallography at Diamond Light Source and NMR at Rutherford Appleton Laboratory. Computational modeling and network analysis are conducted in collaborations with Institute for Advanced Study and Santa Fe Institute.

Clinical relevance and diseases

Aberrant signaling underlies cancers studied at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, immunodeficiencies researched at National Institutes of Health Clinical Center, metabolic disorders examined at Joslin Diabetes Center, and neurodegenerative diseases investigated at Massachusetts General Hospital and Mayo Clinic. Targeted therapies such as kinase inhibitors developed by Novartis, monoclonal antibodies from Genentech, and CAR-T cell therapies pioneered at University of Pennsylvania translate signaling knowledge into treatments. Diagnostic assays leveraging pathway biomarkers are deployed in clinical laboratories at Mayo Clinic and regulatory review by U.S. Food and Drug Administration.

Category:Cell signaling